IDEXX Laboratories Inc/DE, commonly known as IDXX, is a globally recognized leader in pet healthcare innovation. The company is committed to enhance the health and well-being of pets, people, and livestock. Being a member of the S&P 500, their operations are spread over 175 countries across the globe. They stand out in the health industry due to their focus on real-world results, high-quality customer service, and a dedication to improving the health care of pets and livestock. The company is headquartered in Westbrook, Maine.
Primarily, they are involved in developing, producing, and distributing products and services for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. The firm operates in multiple segments including Companion Animal Group (CAG), Water, Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides a suite of in-clinic diagnostic tests and outside reference laboratory services, which are used by veterinarians for advanced patient care. This also includes VetLab Station, Catalyst, SNAP tests, and much more.
The water testing solutions provided by IDXX include easy-to-use, accurate, and cost-effective products to ensure water safety. Livestock, Poultry, and Dairy is another crucial segment operated by IDEXX. To ensure the health of livestock and poultry and to enhance their production, they provide a range of health-based insights derived from SOP-based testing.
What sets IDEXX apart is their devotion to constant technological and scientific innovation. The company’s excellent diagnostics and software are considered game changers by veterinarians worldwide. Their meticulous work has resulted in the development of more rapid and accurate tests for diagnoses such as heartworm disease, Lyme disease, equine infectious anemia, and feline leukemia.
Furthermore, IDEXX is not just a name in the business world but is an active part of society, too. They behave as responsible corporate citizens, emphasizing sustainability, promoting animal welfare, and actively getting involved in philanthropy through the IDEXX foundation.
Financially, the company demonstrates consistent fiscal growth contributing positively to its reputation as a profitable investment.
In conclusion, IDEXX Laboratories Inc/DE (IDXX) has made significant headways in providing innovative healthcare solutions. With an emphasis on enhancing the health of pets, livestock, and people, constant innovation, and a robust corporate responsibility, IDXX stands as an impressive contributor to the health industry. Their diversified operations across multiple sectors and countries further prove their stability and scope in the industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
IDEXX Laboratories Inc. (IDXX) stock increased by 1.14% on Friday, outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average. The company's shares closed at $519.26, still 32.56% below its 52-week high.
IDEXX Laboratories Inc. (IDXX) stock decreased by 1.65% on Thursday, closing at $513.39. This underperformance occurred during a generally negative trading session for the broader market, with both the S&P 500 and Dow Jones Industrial Average also experiencing slight declines. The stock's fall ended a four-day winning streak.
IDEXX Laboratories Inc. (IDXX) saw its stock rise by 1.20% to $521.50 on Tuesday, marking its third consecutive day of gains. This performance occurred on a mixed trading day where the S&P 500 Index remained largely unchanged and the Dow Jones Industrial Average experienced a slight decline.
Two significant acquisitions recently closed in the pet industry, signaling continued growth and investment. IDEXX Laboratories acquired CoVetAI Inc., a provider of AI-powered clinical documentation software for veterinary practices, to enhance its software ecosystem and clinical decision support. Separately, The Farmer's Dog, a fresh dog food company, completed its first acquisition by purchasing Woof, a pet wellness brand known for its refillable enrichment products like the Pupsicle, which will continue to operate independently.
Illumina Inc. has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer. These new hires bring extensive leadership experience from the life sciences, diagnostics, and medical technology sectors, aiming to strengthen Illumina's executive team and drive continued growth and customer service.
IDEXX Laboratories Inc. (IDXX) shares rallied 1.02% to $511.65 on Friday, outperforming the S&P 500 Index which rose 0.17% and the Dow Jones Industrial Average which fell 0.18%. Despite the gain, the stock remains 33.55% below its 52-week high.
IDEXX Laboratories, Inc. (IDXX) announced the acquisition of CoVetAI Inc., a provider of AI-native ambient listening and clinical workflow software for veterinary practices. This acquisition is expected to enhance IDEXX's software ecosystem and diagnostic capabilities, integrating AI to improve workflow efficiency and practice performance. The stock saw a slight gain following the announcement, reflecting positive market sentiment and the company's strategic focus on AI and software integration in the growing veterinary AI diagnostics market.
IDEXX Laboratories has acquired CoVetAI, a provider of AI-native ambient listening and clinical workflow software for veterinary practices. This acquisition aims to enhance IDEXX's software, diagnostics, and AI offerings by making information more accessible and connected across the practice. CoVet's technology helps reduce documentation burden for veterinary teams, allowing them to focus more on patient care, and will integrate with IDEXX's existing ecosystem while continuing to support third-party systems.